Finerenone treatment vs placebo was associated with a reduced risk for new-onset diabetes by 24% among patients with HFmrEF or HFpEF.

Treatment with romosozumab led to improvements in bone microarchitecture among postmenopausal women with osteoporosis.

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

The severity of left ventricular diastolic dysfunction affects risk for incident stroke and transient ischemic attack, as well as major bleeding.

In an extended follow-up study, intensive blood pressure control is associated with reductions in the rate of cognitive impairment.